Illumina (NASDAQ:ILMN) Given New $125.00 Price Target at JPMorgan Chase & Co.

Illumina (NASDAQ:ILMN) had its price objective dropped by JPMorgan Chase & Co. from $130.00 to $125.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has a “neutral” rating on the life sciences company’s stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 0.88% from the company’s previous close.

A number of other analysts also recently issued reports on the stock. Evercore ISI decreased their price objective on shares of Illumina from $195.00 to $175.00 and set an “outperform” rating for the company in a report on Tuesday, June 11th. Jefferies Financial Group initiated coverage on shares of Illumina in a report on Monday, June 3rd. They set a “hold” rating and a $115.00 price objective for the company. StockNews.com began coverage on shares of Illumina in a report on Sunday, June 30th. They set a “buy” rating for the company. TD Cowen reduced their target price on shares of Illumina from $140.00 to $122.00 and set a “hold” rating for the company in a research note on Thursday, June 6th. Finally, Stephens reiterated an “overweight” rating and issued a $170.00 target price on shares of Illumina in a research note on Wednesday, July 10th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, Illumina currently has an average rating of “Hold” and a consensus target price of $151.57.

Illumina Stock Down 2.2 %

NASDAQ ILMN traded down $2.79 on Wednesday, hitting $123.91. 24,137 shares of the company were exchanged, compared to its average volume of 2,110,719. The company has a market cap of $19.74 billion, a PE ratio of -15.55 and a beta of 1.15. Illumina has a 12 month low of $89.00 and a 12 month high of $195.64. The stock has a fifty day moving average of $112.60 and a 200-day moving average of $123.26. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.24. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same period last year, the firm earned $0.32 earnings per share. The business’s quarterly revenue was down 5.4% compared to the same quarter last year. As a group, analysts forecast that Illumina will post 1.5 earnings per share for the current year.

Hedge Funds Weigh In On Illumina

A number of hedge funds have recently made changes to their positions in the company. Raymond James Financial Services Advisors Inc. lifted its position in Illumina by 22.6% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 8,576 shares of the life sciences company’s stock worth $1,194,000 after buying an additional 1,582 shares in the last quarter. Private Trust Co. NA lifted its position in Illumina by 42.9% during the fourth quarter. Private Trust Co. NA now owns 756 shares of the life sciences company’s stock worth $105,000 after buying an additional 227 shares in the last quarter. International Assets Investment Management LLC lifted its position in Illumina by 210.5% during the fourth quarter. International Assets Investment Management LLC now owns 48,194 shares of the life sciences company’s stock worth $6,711,000 after buying an additional 32,672 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in Illumina by 238.1% during the fourth quarter. Nisa Investment Advisors LLC now owns 31,844 shares of the life sciences company’s stock worth $4,434,000 after buying an additional 22,425 shares in the last quarter. Finally, RFG Advisory LLC lifted its position in Illumina by 41.0% during the fourth quarter. RFG Advisory LLC now owns 3,267 shares of the life sciences company’s stock worth $455,000 after buying an additional 950 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.